Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

Antagonist of Secondary Lymphoid-Tissue Chemokine (CCR Ligand 21) Prevents the Development of Chronic Graft-Versus-Host Disease in Mice

“…The use of donor lymphocyte infusion to treat relapsed disease or to achieve full donor chimerism has resulted in the development of chronic GVHD. Furthermore, there is evidence to suggest that patients receiving allogeneic PBSCT have a lower incidence of acute GVHD but an equally high or a higher incidence of chronic GVHD than comparable patients receiving marrow grafts (3)(4)(5)(6)(7). Although the reason for this is unknown, it may be due to the transfer of a significantly larger dose of mature, immunocompetent T cells.…”

“…In recent years, peripheral blood stem cells have largely replaced bone marrow as a peripheral source of allogeneic stem cells because of their relative ease of collection, quicker engraftment kinetics, and economic advantages. The incidence of chronic GVHD has been reported to be higher after peripheral blood stem cell transplantation (PBSCT) than after bone marrow transplantation, whereas the incidence of acute GVHD after PBSCT is not significantly higher (3)(4)(5)(6)(7). Acute GVHD is a rapidly progressive, unrelenting, systemic illness characterized by immunosuppression, cachexia, and tissue injury of the skin, liver, and intestinal mucosa.…”

Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone

“…[1][2][3][4][5][6][7][8] Nevertheless, in only a minority of the randomized comparative trials did this translate into an overall survival advantage and some studies suggested the use of G-CSF mobilized PBPC was associated with a greater risk of either acute or chronic graft-versus-host disease (GVHD), or both. 6,[8][9][10] In two recent retrospective studies in patients with aplastic anemia or children with leukemia performed by the International Bone Marrow Transplant Registry, transplantation of G-CSF mobilized PBPC was associated with higher rates of GVHD.…”

Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma

“…Hematopoietic stem cells (HSC) are found not only in the bone marrow but also in the peripheral blood and cord blood, and therefore HSC transplantation has been recently carried out utilizing allogeneic peripheral-blood stem cells and cord blood stem cells [1,2]. In particular, cord blood stem-cell transplantation (CBT) has been successfully performed numerous times over the past decade and remains an attractive option since donor coordination is not necessary and the incidence and severity of acute graft-versus-host disease are lower than those of BMT or allogeneic peripheral-blood stem-cell transplantation (PBSCT) [2].…”